{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:38Z","timestamp":1788401618286,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013986","name":"Government of the United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013986","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jinf.2025.106663","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:39:09Z","timestamp":1764607149000},"page":"106663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial"],"prefix":"10.1016","volume":"92","author":[{"given":"E.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Greenland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"de Whalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.C.","family":"Macaulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.K.","family":"Aley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Plested","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Koleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kinch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Madupuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.C.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.J.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Cathie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.N.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Shackley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"O\u2019 Riordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Polychronakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Trari Belhadef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Mujadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Singha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cantrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Clutterbuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Anslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Nguyen-Van-Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Snape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Minassian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.jinf.2025.106663_bib1","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jinf.2025.106663_bib2","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/jmv.27688","article-title":"Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: a systematic review","volume":"94","author":"Notarte","year":"2022","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.jinf.2025.106663_bib3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.15585\/mmwr.mm7104e4","article-title":"Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods - United States, December 2020-January 2022","volume":"71","author":"Iuliano","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"22","key":"10.1016\/j.jinf.2025.106663_bib4","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1001\/jama.2022.7493","article-title":"Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance","volume":"327","author":"Fleming-Dutra","year":"2022","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.jinf.2025.106663_bib5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.15585\/mmwr.mm7315a2","article-title":"Durability of original monovalent mRNA vaccine effectiveness against COVID-19 Omicron-associated hospitalization in children and adolescents - United States, 2021-2023","volume":"73","author":"Zambrano","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"10.1016\/j.jinf.2025.106663_bib6","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2202826","article-title":"BNT162b2 protection against the Omicron variant in children and adolescents","volume":"386","author":"Price","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jinf.2025.106663_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.25162","article-title":"Effectiveness associated with BNT162b2 vaccine against emergency department and urgent care encounters for Delta and Omicron SARS-CoV-2 infection among adolescents aged 12 to 17 years","volume":"5","author":"Tartof","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.jinf.2025.106663_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jinf.2025.106663_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jinf.2025.106663_bib10","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1038\/s41467-022-31485-z","article-title":"Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents","volume":"13","author":"Rosa Duque","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.jinf.2025.106663_bib11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.122.059970","article-title":"Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex","volume":"146","author":"Patone","year":"2022","journal-title":"Circulation"},{"issue":"10324","key":"10.1016\/j.jinf.2025.106663_bib12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2025.106663_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074325","article-title":"Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses","volume":"382","author":"Andersson","year":"2023","journal-title":"BMJ"},{"issue":"10318","key":"10.1016\/j.jinf.2025.106663_bib14","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jinf.2025.106663_bib15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jinf.2022.04.018","article-title":"Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial","volume":"84","author":"Liu","year":"2022","journal-title":"J Infect"},{"issue":"3","key":"10.1016\/j.jinf.2025.106663_bib16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jinf.2023.06.007","article-title":"Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): a randomised controlled trial","volume":"87","author":"Kelly","year":"2023","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jinf.2025.106663_bib17","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1002\/cpim.116","article-title":"Development of a rapid focus reduction neutralization test assay for measuring SARS-CoV-2 neutralizing antibodies","volume":"131","author":"Vanderheiden","year":"2020","journal-title":"Curr Protoc Immunol"},{"key":"10.1016\/j.jinf.2025.106663_bib18","unstructured":"Medicines & Healthcare Products Regulatory Agency,\u00a0Comirnaty 10 micrograms\/dose concentrate for dispersion for injection COVID-19 mRNA vaccine, summary of product characteristics (SmPC),\u00a02024. \u3008https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/0fbd8cb9af4abfc2a67350cc80f4f71c2e9900ca\u3009."},{"key":"10.1016\/j.jinf.2025.106663_bib19","unstructured":"Medicines & Healthcare Products Regulatory Agency, Comirnaty 30 micrograms\/dose dispersion for injection COVID-19 mRNA vaccine, summary of product characteristics (SmPC) 2024. \u3008https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/f10eb9d71c2d0280fb5bb2510078224d73f8d7ef\u3009."},{"issue":"8","key":"10.1016\/j.jinf.2025.106663_bib20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","article-title":"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial","volume":"10","author":"Li","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.jinf.2025.106663_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jinf.2023.06.007","article-title":"Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): a randomised controlled trial","volume":"87","author":"Kelly","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2025.106663_bib22","doi-asserted-by":"crossref","first-page":"100211","DOI":"10.1016\/j.jvacx.2022.100211","article-title":"Heterologous prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among healthy Thai adolescents","volume":"12","author":"Puthanakit","year":"2022","journal-title":"Vaccine X"},{"issue":"9","key":"10.1016\/j.jinf.2025.106663_bib23","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/s41591-023-02503-4","article-title":"Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial","volume":"29","author":"Branche","year":"2023","journal-title":"Nat Med"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325002634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325002634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:11:37Z","timestamp":1771542697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445325002634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0163445325002634"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106663","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106663"}}